Answers are grounded in this paper and cite their sources.
Case report shows long-term disease control in a patient with unresectable small-cell neuroendocrine carcinoma, suggesting potential treatment strategies.
Small-cell neuroendocrine carcinoma of the gallbladder (SCNEC-GB) is an exceptionally rare and aggressive malignancy, representing fewer than 2% of gallbladder cancers. Most patients present with advanced, unresectable disease, and survival rarely exceeds one year despite therapy. We describe a patient in whom SCNEC-GB was discovered incidentally during routine preoperative work-up for hernia repair. Imaging revealed a bulky gallbladder mass with hepatic invasion and regional lymphadenopathy, pathology confirmed small-cell NEC with a Ki-67 - 100%. A multidisciplinary tumor board deemed the tumor unresectable, and systemic treatment was initiated. The patient received six cycles of platinum-etoposide chemotherapy, which achieved marked regression, followed by hypofractionated radiotherapy to the residual primary and nodal sites. Follow-up PET/CT demonstrated complete radiological and metabolic response. The patient has now maintained long-term disease control for more than 18 months, with no evidence of recurrence or new metastases. Such durable remission in advanced SCNEC-GB is extraordinarily uncommon. This case highlights the potential of multimodal therapy to achieve long-term disease control in unresectable disease and underscores the need for collaborative efforts to define optimal strategies for this rare and lethal malignancy.
No takes yet. Share an insight, caveat, or question.
Salim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: